The Pharmaceutical Market: South Africa Opportunities and Challenges

Publisher Name :
Date: 08-Nov-2012
No. of pages: 103
Inquire Before Buying

OVERVIEW OF THE PHARMACEUTICAL MARKET IN SOUTH AFRICA

The government drive to support local production and reduce the country's reliance on imports, in addition to global epidemiological and demographic trends, are all positive factors contributing to long-term growth in the pharmaceutical market. However, deep segregation between private and public healthcare facilities continues to leave the vast majority of the population without medical care. BMI believes this will be rectified through the creation of the National Health Insurance scheme over the next decade, but in the meantime unemployment, lack of education and geographical inaccessibility to healthcare for the wider population will continue to hinder growth in the market.

Headline Expenditure Projections Pharmaceuticals: ZAR27.19bn (US$3.74bn) in 2011 to ZAR29.61bn (US$3.61bn) in 2012; +8.9% in local currency and -3.5% in US dollar terms. Healthcare: ZAR261.51bn (US$36.01bn) in 2011 to ZAR285.26bn (US$34.79bn) in 2012; +9.1% in local currency terms and -3.4% in US dollar terms. Medical devices: ZAR11.43bn (US$1.57bn) in 2011 to ZAR12.19bn (US$1.49bn) in 2012; +6.7% in local currency terms and -5.5% in US dollar terms. Forecast changed due to depreciation of the South African rand.

Product Description

The South Africa Pharmaceuticals & Healthcare Report features Espicom's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

Espicom's South Africa Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the South Africa pharmaceutical and healthcare industry.

Key Benefits


  • Benchmark Espicom's independent pharmaceutical and healthcare industry forecasts to test other views - a key input for successful budgeting and strategic business planning in the South Africa pharmaceutical and healthcare market.

  • Target business opportunities and risks in the pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in South Africa.

  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.


Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Espicom's forecast analysis, and taken together with Espicom's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Espicom Industry Forecasts
Forecasts to end-2016 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:


  • Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

  • Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

  • Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

  • Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

  • OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

  • Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.


Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of Espicom's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

The Pharmaceutical Market: South Africa Opportunities and Challenges

EXECUTIVE SUMMARY... 1
Snapshot: Strategic Espicom Analysis.........2
Snapshot: Key Data Projections......3

MACROENVIRONMENT . 4

POLITICAL.....4

ECONOMIC...5
Projections...........5

LEGAL............6

DEMOGRAPHIC........7
Projections...........7
Latest Figures.......8
Demographic Indicators..9
Birth Rate... 9
Death Rate. 9
Infant MortalityRate (IMR) 9
Life Expectancy at Birth.... 9

EPIDEMIOLOGY............ 10

DISEASE BURDEN...10

DISEASE PREVALENCE........11
Communicable Diseases11
HIV/AIDS... 11
Malaria...... 11
TB.. 12
Non-Communicable Diseases....12
Cancer....... 12

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS.. 13

ORGANISATION......13
National Health Insurance..........13

EXPENDITURE.........14
Projections.........14
Latest Figures.....15

INFRASTRUCTURE..16
Hospital Infrastructure..16
Netcare Group ..... 17
Hospital Bed Provision...17

WORKFORCE...........18
Projections.........18
Physicians...........19
Public Workforce............19

REGULATORY AFFAIRS 20

NATIONAL AUTHORITY..... 20

MARKETING REGISTRATION.......... 20
National Procedures.......20

TRADE REGULATIONS ........21
Parallel Trade.....21

PRICING & REIMBURSEMENT... 22

NATIONAL AUTHORITY..... 22

PRICING...... 22
Dispensing Fees Charged by Pharmacists..........22

REIMBURSEMENT . 23
Essential Drugs List........23

DISTRIBUTION CHANNELS....... 24

DRUG RETAILING....24
Public Pharmacies............24
Private Pharmacies..........24
Pharmacy Trade Association......25
USAP.........25
Leading Pharmacy Chains..........25
Clicks.........25
Dischem...25
Medipost Courier Pharmacy.......25

MARKET ANALYSIS....... 26

SIZE 26
Projections.........26
Historical Figures............28
Current Structure............29
ARV Tender...........30

PRODUCT DEVELOPMENT 30

MANUFACTURING. 30

TRADE.........31
Exports..31
Imports..33
Balance of Trade38

COMPETITION.. 39

TRADE ASSOCIATION..........39

PIASA........39

COMPANY INTELLIGENCE. 40
Adcock Ingram.....40
Aspen Pharmacare...........40
Merck South Africa........... 41
Competitive Strategies..41
OTC PHARMACEUTICALS.......... 43

MARKET SIZE...........43

COMPETITION.........43
Trade Association...........43
SMASA......43

GENERIC PHARMACEUTICALS 44

MARKET SIZE.......... 44

COMPETITION........ 44
Trade Association...........44
NAPM........44
Company Intelligence....45
Aspen Pharmacare...........45
Cipla Medpro........45
Ranbaxy...45

BIOLOGICS & BIOSIMILARS......46

PRODUCT DEVELOPMENT 46
Lifelab.......46
TIA46

COMPETITION........ 46
Trade Association...........46
IMSA..........46
Company Intelligence....47
Arvir Technologies........... 47
Bioclones.. 47
Elevation Biotech. 47
iThemba Pharmaceuticals........... 47
Key Oncologics..... 47
National Bioproducts Institute... 47

CONCLUSIONS: OPPORTUNITIES & CHALLENGES.........48
Strategic Espicom Analysis............ 48
MACROENVIRONMENT...48
EPIDEMIOLOGY..48
HEALTHCARE......48
REGULATORY AFFAIRS....49
PRICING & REIMBURSEMENT......49
DISTRIBUTION CHANNELS..........50
MARKET.50
COMPETITION ....51
OTC PHARMACEUTICALS51
GENERIC PHARMACEUTICALS.....51
BIOLOGICS & BIOSIMILARS.........51
Radar Analysis........53
SWOT Analysis........53

DIRECTORY...... 54

COMPETITION........ 54
Pharmaceutical Companies........54
Generic Companies........54
Biologic Companies........54

GOVERNMENT ORGANISATIONS.. 54

PRODUCT DEVELOPMENT 54

TRADE ORGANISATIONS... 54

List of Tables
Espicom Analysis of the Pharmaceutical Market, 2012.. 2
Key Data Projections, 2011-2016.......... 3
Political Landscape, 2012........ 4
Regional Ranking of Projected Economies, 2016........... 5
Projected Economy, 2011-2016............ 5
Regional Ranking of Projected Demographics, 2016..... 7
Projected Demographics, 2011-2016... 7
Population by Gender & Province, 2011............ 8
Population by Gender & Age, 2011...... 8
Births, Deaths & Natural Increase, 1997-2010.. 9
Selected Causes of Death by Sex, 2007-2009.. 10
Estimated Number of Adults & Children Receiving ART, 2005-2010.......11
Reported Cases of Selected Communicble Diseases, 1990-201012
Regional Ranking of Projected Health Expenditure, 2016........ 14
Projected Health Expenditure, 2011-2016....... 14
Health Funding by Sector, 2007/08-2009/10 (Rand Millions)...15
Public Sector Hospitals by Province, 2004-2011........... 16
Private Sector Hospitals by Province, 2004-2010......... 16
Public Sector Hospital Beds by Province, 2005-2009....17
Private Sector Hospital Beds by Province, 1998-2010...17
Regional Ranking of Projected Physicians, 2016.......... 18
Projected Physicians, 2011-2016........ 18
Physicians by Province, 2009-2011.... 19
Public Physicians, Nurses, Dentists & Pharmacists, 2000-2011 19
Regional Ranking of Projected Pharmaceutical Markets, 2016 26
Projected Pharmaceutical Market at Retail Prices, 2011-2016.. 28
Historical Pharmaceutical Market at Retail Prices, 1995-2010. 28
Pharmaceutical Retail Sales by Month at Current Prices, 2005-2011 (R Millions) 29
Pharmaceutical Exports by Category, 1995-2010 (US$000s).... 31
Pharmaceutical Exports by Country/Region, 2010 (US$000s).. 32
Pharmaceutical Imports by Category, 1995-2010 (US$000s)... 33
Imports of Raw Materials by Country/Region, 2010 (US$000s)............ 35
Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s).... 36
Imports of Medicaments by Country/Region, 2010 (US$000s) 37
Balance of Pharmaceutical Trade, 1995-2010 (US$000s)......... 38
Member Companies of PIASA, 2011... 39
Member Companies of SMASA, 2011. 43
Member Companies of NAPM, 2011..44
Member Companies of IMSA, 2011....46
Espicom Analysis of the Pharmaceutical Market, 2012 52
SWOT Analysis of the Pharmaceutical Market, 2012... 53

List of Charts
Regional Comparison of Projected Pharmaceutical Markets at Retail Prices, 2016 27
Regional Comparison of Projected Pharmaceutical Market Share, 2016........... 27
Historical Pharmaceutical Market at Retail Prices, 1995-2010. 29
Pharmaceutical Exports, 1995-2010 (US$ Millions) .... 31
Pharmaceutical Imports, 1995-2010 (US$ Millions).... 33
Pharmaceutical Imports by Country/Region, 2010 (%)............ 34
Balance of Pharmaceutical Trade, 1995-2010 (US$ Millions)... 38
Radar Graph of the Pharmaceutical Market, 2012...... 53

  • Global Letrozole Market Professional Survey Report 2016
    Published: 02-Dec-2016        Price: US 3500 Onwards        Pages: 106
    Notes: Production, means the output of Letrozole Revenue, means the sales value of Letrozole This report studies Letrozole in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manuf......
  • Europe Intravenous Solution Market Report 2016
    Published: 02-Dec-2016        Price: US 3900 Onwards        Pages: 104
    Notes: Sales, means the sales volume of Intravenous Solution Revenue, means the sales value of Intravenous Solution This report studies sales (consumption) of Intravenous Solution in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Baxter (US) - Braun Medical Inc. (US) - AIN MEDIC......
  • Global Penicillin Market Professional Survey Report 2016
    Published: 02-Dec-2016        Price: US 3500 Onwards        Pages: 112
    Notes: Production, means the output of Penicillin Revenue, means the sales value of Penicillin This report studies Penicillin in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each ma......
  • China Vitro Diagnostics Reagent Market Research Report 2016
    Published: 02-Dec-2016        Price: US 3200 Onwards        Pages: 112
    Notes: Sales, means the sales volume of Vitro Diagnostics Reagent Revenue, means the sales value of Vitro Diagnostics Reagent This report studies Vitro Diagnostics Reagent in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Roche - Siemens - Abbott - Beckman - BD - Johnson & Johnson - BioMerieux - Bio-Rad ......
  • Europe Dolutegravir Market Report 2016
    Published: 02-Dec-2016        Price: US 3900 Onwards        Pages: 109
    Notes: Sales, means the sales volume of Dolutegravir Revenue, means the sales value of Dolutegravir This report studies sales (consumption) of Dolutegravir in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - GSK - DESANO Market Segment by Countries, this report splits Euro......
  • United States, EU, Japan, China, India and Southeast Asia Scar Treatment Market Size, Status and Forecast 2021
    Published: 02-Dec-2016        Price: US 3300 Onwards        Pages: 107
    Notes: Production, means the output of Scar Treatment Revenue, means the sales value of Scar Treatment This report studies the global Scar Treatment market, analyzes and researches the Scar Treatment development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Avita Medical - CCA Industries - Enaltus - Oculus Innovative Sciences - Pacifi......
  • Europe Glimepiride Market Report 2016
    Published: 02-Dec-2016        Price: US 3900 Onwards        Pages: 106
    Notes: Sales, means the sales volume of Glimepiride Revenue, means the sales value of Glimepiride This report studies sales (consumption) of Glimepiride in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Sanofi-Aventis - Wanbang Biopharmaceuticals - Cspc Pharmaceutical - T......
  • Global Calcium Channel Blocker Market Research Report 2016
    Published: 02-Dec-2016        Price: US 2900 Onwards        Pages: 103
    Notes: Production, means the output of Calcium Channel Blocker Revenue, means the sales value of Calcium Channel Blocker This report studies Calcium Channel Blocker in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Pfizer - Aventis - Searle - Bayer - AstraZenec......
  • Global Autolytic Debridement Sales Market Report 2016
    Published: 02-Dec-2016        Price: US 4000 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Autolytic Debridement Revenue, means the sales value of Autolytic Debridement This report studies sales (consumption) of Autolytic Debridement in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Advanced Medical Solutions Group plc (UK) - ArthroCare Corporatio......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs